Treatment of homologous recombination proficient ovarian cancer and parp inhibitor-resistant tumors using PP2A RE-activation strategies

The University of Michigan will receive $702,000 under a three-year Project Grant award from the Department of the Army Medical Command to support research into new treatment strategies for ovarian cancer and PARP inhibitor-resistant tumors. The grant funding, provided through the Military Medical Research and Development program, will allow University researchers to investigate techniques for re-activating Protein Phosphatase 2A (PP2A) as a potential means of treating homologous recombination proficient ovarian cancers and tumors resistant to poly (ADP-ribose) polymerase inhibitors. The Military Medical Research and Development program aims to advance biomedical research that can improve health care for service members and the general public through innovative and impactful solutions applicable to both civilian and battlefield medicine. The University of Michigan grant activities align with this goal by exploring new medical approaches with the potential to benefit those with difficult-to-treat cancers.